Login
IMMUNIC, INC. logo

IMMUNIC, INC.

imux.com

What Do They Do?

Develops oral drug candidates for patients with neurologic, gastrointestinal, inflammatory and autoimmune diseases.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −65% (Loss)
vs −$25.6M in Q3 FY2025
  • Aug 6, 2026 CEO Daniel Vitt left the company His employment ended on August 7, and he agreed to chair the Scientific Advisory Board.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support